



24 October 2022

ASX ANNOUNCEMENT

Amendment to AGM Notice - Withdrawal of Resolution

ImpediMed Limited (ASX:IPD) (**Impedimed, Company**) is pleased to provide an update in respect of the Notice of Annual General Meeting (**AGM**) released to the ASX on 22 September 2022 for the upcoming 2022 AGM to be held on 26 October 2022 (**Meeting**). Based on feedback from shareholders, the Board has elected to withdraw the resolution in Item 5 (Approval for an additional 10% capacity to issued equity securities under ASX Listing Rule 7.1A).

The Board and Management have recently confirmed a commitment to improved two-way dialogue with the shareholders of ImpediMed. As a part of this commitment, the Chairman of ImpediMed, Don Williams, and Interim CEO and Director, Dave Anderson, have been conducting face to face meetings with shareholders since arriving in Australia this past week.

A discussion was held with certain shareholders regarding the need for the resolution in Item 5, given the strong cash position of the Company. The Board agrees that the Company has adequate cash resources to reach cash flow breakeven and has therefore withdrawn this resolution from the Meeting. The Board appreciates the feedback provided and looks forward to a continued dialogue with shareholders.

The withdrawal of the resolution in Item 5 will have no material adverse impact on the Company and will not impact the validity of voting forms or any proxy or direct votes already submitted in respect of the remaining items of business. All other items of business included in the Notice of Meeting for the AGM will be put to shareholders.

This announcement was approved for release by ImpediMed Limited's Board of Directors.

Contact Details

Investor relations Contact:

Mike Bassett, ImpediMed

T: +61 407 431 432

E: mbassett@impedimed.com

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is a medical software technology company that non-invasively measures, monitors and manages fluid status and tissue composition using bioimpedance spectroscopy (BIS).

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO® for multiple indications including heart failure, lymphoedema, and protein calorie malnutrition, sold in select markets globally.

For more information, visit www.impedimed.com.

Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to expand sales and market acceptance in the US and Australia including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialise new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. ImpediMed does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. ImpediMed may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.